To identify factors associated with tolerance and survival after noninvasive positive-pressure ventilation (NIPPV) and to investigate the influence of NIPPV on lung function in patients with ALS. Methods: NIPPV was offered to 71 patients with ALS in accordance with currently published guidelines. Effects of NIPPV on lung function and factors influencing tolerance and survival after NIPPV were studied. Results: Forty-four patients (61.9%; 95% CI: 50.6 to 73.2) tolerated NIPPV (NIPPV use Ն4 h/day) and 27 (38.1%; 95% CI: 26.8 to 49.4) were intolerant (NIPPV use Ͻ4 h/day). Patients with mild or moderate bulbar symptoms were more likely to tolerate NIPPV than those with severe impairment (odds ratio ϭ 6.09, 95% CI: 1.18 to 31.52, p ϭ 0.031). After NIPPV introduction, a slower decline in forced vital capacity (FVC) was observed in tolerant vs intolerant patients (p ϭ 0.002). The slope of FVC decline after NIPPV initiation (risk ratio [RR]: 0.78, 95% CI: 0.65 to 0.94, p ϭ 0.01) together with NIPPV tolerance (RR: 0.32, 95% CI: 0.13 to 0.78, p ϭ 0.013) were the only independent predictors of survival in the overall group of patients. In multivariate analysis, body mass index was the most powerful predictor of longer survival after NIPPV in tolerant patients (RR: 0.77, 95% CI: 0.61 to 0.96, p ϭ 0.022). Conclusion: Survival after noninvasive ventilation was independently related to ventilatory use (Ն4 h/day) and to the modifications of forced vital capacity decline after treatment initiation. The severity of bulbar impairment and the nutritional status of the ALS patients at the introduction of ventilation may predict tolerance and survival. NEUROLOGY 2006;67:761-765 Current guidelines suggest provision of noninvasive positive-pressure ventilation (NIPPV) for symptomatic hypoventilation in ALS.
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Current guidelines suggest provision of noninvasive positive-pressure ventilation (NIPPV) for symptomatic hypoventilation in ALS. 1, 2 However, only a small proportion of potentially eligible patients are referred for NIPPV worldwide, 3, 4 possibly reflecting the fear of prolonged survival in the face of increasing disability as well as the poor knowledge about the influence of bulbar involvement and physical dysfunction on NIPPV treatment. It is unclear whether NIPPV alters pulmonary function and uncertain which variables best predict benefit from NIPPV.
Therefore, we performed a prospective study aimed to identify factors associated with tolerance and survival and to investigate the influence of NIPPV on lung function.
Methods. Patients and procedures.
We prospectively collected data and included consecutive patients who came to the ALS Center for an initial visit between October 1999 and July 2003. Patients were diagnosed as definite or probable ALS according to the El Escorial World Federation of Neurology revised criteria. 5 Patients were excluded if they had primary lateral sclerosis or if a diagnosis other than ALS was made during follow-up.
Patients were seen routinely every 1 to 3 months, and pulmonary function testing was performed during all the visits. Daytime partial pressure of arterial oxygen (PaO 2 ) and partial pressure of arterial carbon dioxide (PaCO 2 ) were established by arterial blood gas analyses. Nocturnal pulse oximetry (oxyhemoglobin saturation as measured by pulse oximetry [SpO 2 ]) was also performed every 3 to 5 months. In accordance with published guidelines, 1,2 NIPPV was offered when patients presented respiratory symptoms (such as dyspnea, morning headache, daytime hypersomnolence) or one of the following: forced vital capacity (FVC) Ͻ50% of predicted value or maximal static inspiratory pressure (MIP) less than Ϫ60 cm H 2 O, PaCO 2 Ն45 mm Hg, nocturnal desaturation (defined as SaO 2 Ͻ88% for five consecutive minutes).
Parameters collected for each patient included serial FVC (percentage of predicted, FVC%), date of diagnosis and area of onset, severity of bulbar symptoms, use of riluzole, body mass index (BMI) at the time of NIPPV, percutaneous endoscopic gastrostomy tube placement, date that NIPPV was offered, number of hours of ventilation per day (recorded automatically by the ventilator), and time of death. BMI was calculated as follows: BMI ϭ weight (kg)/height 2 (m). Functional impairment due to ALS was evaluated using the ALS Functional Rating Scale (ALS-FRS), 6 a 10-item, 40-point scale that measures bulbar, upper extremity, lower extremity, and respiratory functions. Scores range from 0 (severe impairment) to 40 (normal functioning). Bulbar symptoms were classified as absent or mild, moderate, and severe based on a 0-to 8-point scale assessing speech and swallowing impairment derived from the ALS-FRS. FVC variation over time (FVC% slope)
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was calculated for each patient separately before and after NIPPV initiation as the slope of a straight-line model by the least squares method.
NIPPV was established in the hospital during an inpatient admission using a bilevel positive-pressure ventilator (BiPAP; Respironics Ltd., Vitalaire, Italy) in spontaneous-timed mode, with pressures adjusted in the clinic to patient comfort, leaks, and efficiency of ventilation. Ventilator settings were titrated to maintain normal daytime PaO 2 , PaCO 2 , SpO 2 and to relieve patient's symptoms. Applied pressures started with low inspiratory pressures (8 to 12 cm H 2 O) and were gradually titrated upward as tolerated by the patient. Expiratory pressures ranged from 3 to 4 cm H 2 O. Patients were instructed to use NIPPV for as long as tolerated at night and as necessary in the daytime. To maximize compliance, alternate interfaces were used as necessary (nasal, oronasal, total face masks, and mouth pieces), nasal steroid sprays were used for nasal congestion, and suction devices for clearance of secretions. All patients were also taught assisted cough techniques by an experienced respiratory physiotherapist, including mechanical insufflators-exsufflators.
After NIPPV introduction, lung function was assessed every month for the first 3 months and then at 2-to 3-month intervals thereafter.
Tolerance of NIPPV was defined within 60 days from initiation 2 as ventilator use Ն4 h/day, so that patients were divided into two groups: tolerant of NIPPV (use of ventilatory device Ն4 h/day) and intolerant of NIPPV (use of ventilatory device for Ͻ4 h/day). [7] [8] [9] All patients were followed to death or tracheostomy or for at least 30 months after NIPPV initiation.
Data analysis. Our hypotheses were that 1) tolerance of NIPPV and survival after treatment introduction would depend on key demographic and clinical variables in the whole sample of patients and in the tolerant group and 2) NIPPV use (Ն4 h/day) would modify the FVC decline. To have an 80% chance of detecting the expected survival benefit 7,9 at the 0.05 significance level required a minimum of 60 patients. The generalized Fisher exact (Fisher-Freeman-Halton) test was performed as a test of independence among categorical variables. Mann-Whitney U test was used for continuous variables. Kaplan-Meier analysis was performed to analyze survival curves, and the log rank test was performed for comparing Kaplan-Meier curves. Univariable and multivariable logistic regression were used to assess the relationship between NIPPV tolerance and the variables studied. The Cox stepwise proportional hazard model was used to study the prognostic factors for survival. Analyses were not corrected for multiple comparisons because of the exploratory nature of the study.
Results. Demographic and clinical characteristics of the patients.
Seventy-one patients with ALS were included in the study. The main demographic and clinical characteristics of the patients are reported in table 1. All patients were using riluzole (50 mg twice daily). No patient was known to have a history of chronic lung disease, obstructive sleep apnea syndrome, or heart failure. No patient was lost at follow-up. Forty-four (61.9%; 95% CI: 50.6 to 73.2) patients were tolerant of NIPPV and 27 (38.1%; 95% CI: 26.2 to 49.4) were intolerant. Mean NIPPV use was 7.14 Ϯ 0.38 h/day for tolerant patients and 2.04 Ϯ 0.54 h/day for intolerant patients. Patients in the two groups were not significantly different except that tolerant patients were less likely to present a severe bulbar involvement at NIPPV introduction than intolerant patients (p ϭ 0.031; table 1).
Effect of NIPPV on survival. There was longer survival in tolerant vs intolerant patients (p ϭ 0.0001). The median survival time after NIPPV was 18 months (interquartile range 7 to 28) for tolerant patients and 6 months (interquartile range 3 to 12) for intolerant patients. At the end of the study (February 2006) , nine patients were still alive. Median total survival from disease onset was 52 months for tolerant and 34 months for intolerant patients (p ϭ 0.0032). Effect of NIPPV on lung function. There was no significant difference in the median FVC% slope before NIPPV initiation in the two groups (Ϫ2.92 for tolerant and Ϫ4.0 for intolerant patients; p ϭ 0.1). Interestingly, tolerant patients showed a slower FVC% slope following NIPPV initiation than intolerant patients (Ϫ0.5 for tolerant and Ϫ3.46 for intolerant patients; p ϭ 0.002). Moreover, when we compared the FVC% slope before and after NIPPV initiation, we found that tolerant patients showed a slower rate of decline post-intervention (p ϭ 0.012); on the contrary, the difference was not significant for intolerant patients (p ϭ 0.91). No evidence was found of an early negative effect of NIPPV on FVC; median FVC% at the time of NIPPV was 45% for tolerant and intolerant patients, 44% for tolerant, and 41% for intolerant patients after 1 month of NIPPV use (p ϭ 0.362).
Factors influencing survival after NIPPV. We performed multiple regression analysis with the Cox stepwise proportional hazards model to identify independent predictors of survival after NIPPV introduction. In univariate analysis, factors influencing the outcome after NIPPV were as follows: tolerance of NIPPV (use of the device Ն4 h/day; p ϭ 0.0001), FVC% slope after NIPPV introduction (p ϭ 0.0001), BMI (p ϭ 0.005), and ALS-FRS score at time of NIPPV (p ϭ 0.040). Multiple regression analysis showed that FVC% slope after NIPPV initiation and tolerance of NIPPV were the only independent predictors of survival (table 3) . The associations were maintained after adjustment for age, gender, and severity of bulbar symptoms.
Factors influencing survival after NIPPV in the tolerant patients. We analyzed separately the group of tolerant patients to identify potential parameters significantly associated with longer survival in this group of subjects. In univariate analysis, factors influencing the outcome after NIPPV were FVC% (p ϭ 0.045) and BMI (p ϭ 0.014).
Multivariate analysis (Cox stepwise proportional hazard model) showed that BMI was the only independent predictor of survival after NIPPV introduction in the patients tolerant of this device (risk ratio: 0.77, 95% CI: 0.61 to 0.96; p ϭ 0.022). We then specifically evaluated the independent effect of BMI on survival in our cohort of tolerant patients using different thresholds and found that the patients with a BMI Ն21 kg/m 2 survived longer than the patients with a BMI Ͻ21 kg/m 2 (median survival 23 vs 9 months, p ϭ 0.0001; figure) . Interestingly, patients in the two groups (BMI greater than and less than 21 kg/m 2 ) were not different regarding all the other demographic and clinical variables examined.
Discussion. In this study, we provide a series of analyses that may help to expand our knowledge about NIPPV in ALS patients. First, we confirmed that NIPPV slows the FVC% decline over time, and this effect, together with NIPPV use (Ն4 h/day), were the only independent predictive factors for survival in the overall group of patients. Second, we demonstrated that mild to moderate bulbar impairment was strongly associated with NIPPV tolerance in our ALS population. Finally, we showed that nu- (p ϭ 0.0001 by the log-rank test) . tritional status of the ALS patients at the time of NIPPV initiation might represent a fundamental predictive factor for survival in the patients tolerant of this device.
Figure. Survival times from noninvasive positive-pressure ventilation (NIPPV) initiation in patients tolerant of ventilation (NIPPV use Ն4 h/day, n ϭ 44) according to body mass index (BMI). Tolerant patients were arbitrary divided into two groups: those with a BMI Ͻ21 kg/m 2 (dotted line, n ϭ 14) and those with a BMI Ն21 kg/m 2 (solid line, n ϭ 30). Survival differed among the two groups
NIPPV has been successfully used to treat respiratory symptoms, and there is considerable evidence that it can prolong survival in ALS. [7] [8] [9] [10] Notwithstanding the effects on respiratory symptoms and survival, many studies suggest that the employment of NIPPV in ALS is poor, 3, 4 and there appears to be a need for more education of clinicians and patients about the benefits of NIPPV earlier in the course of the disease. 11 In agreement with previous studies, [7] [8] [9] [10] including the only randomized trial of NIPPV in ALS, 10 our data confirmed that ventilatory treatment prolongs survival in tolerant patients and provide further evidence to support using NIPPV for symptomatic hypoventilation. 1, 2 It might be argued that, in our sample, tolerant patients tended to be in better initial health at the time of NIPPV introduction. However, although nonresponders tended to show a longer disease duration before NIPPV introduction (p ϭ 0.094) and worse ALS-FRS scores (p ϭ 0.111), these differences were not significant. Patients were also not different according to age (p ϭ 0.646) and site of disease onset (p ϭ 0.646), two well-known negative prognostic factors for survival in ALS. Hence, we do not think that at baseline responders were more likely to have a better outcome than nonresponders.
Among the factors that may be relevant in explaining the low prevalence of NIPPV use, there is the poor knowledge about its effects on declining respiratory function and about the variables that influence patients compliance and survival after its introduction.
Bulbar-onset ALS patients are generally believed to have reduced compliance to the treatment, and thus clinicians may be reluctant to initiate NIPPV in this population. Studies on patients with ALS yield conflicting results: some demonstrated poor tolerance and efficacy in the patients with bulbar onset, 7, 12, 13 whereas another reported benefit. 9 In our population, bulbar onset was not associated with poor NIPPV tolerance. However, patients with mild or moderate bulbar impairment resulted six times more likely to tolerate NIPPV than those with severe involvement, suggesting that severity of bulbar symptoms, more than site of ALS onset, might represent an important prognostic factor for NIPPV compliance. Furthermore, in agreement with a previous study 7 that found persistence of survival benefit after stratification for bulbar symptoms, in our ALS population, survival after NIPPV was not related to severity of bulbar impairment. Our results, then, suggest that great attention should be paid to severity of bulbar symptoms at the time of NIPPV introduction and great efforts should be made to maximize compliance in this group of patients.
Another important aspect that we have investigated in this study regards the effects of NIPPV on the rate of respiratory function decline in ALS patients. Studies reported contrasting results: one suggested that NIPPV slows the decline of FVC%, 9 whereas another reported that NIPPV was associated with a fall in FVC% at initiation of the treatment, but no change in the rate of decline. 8 In our ALS population, use of NIPPV (Ն4 h/day) significantly slowed the decline of FVC% over time, and most importantly, this change was significantly associated with survival. Possible explanations of the effect of NIPPV on respiratory muscle function could be related to alleviation of microatelectasis, amelioration of overall lung compliance, and to the intermittent rest provided by respiratory devices to respiratory muscles.
14 Our study, then, strongly support the hypothesis that NIPPV could prove useful in modifying the relentless pulmonary function impairment of ALS patients.
Finally, because the clinical predictors of benefit from NIPPV are still largely unexplored, we investigated the factors potentially related to survival in the NIPPV tolerant patients. We found that BMI at the time of introduction of the treatment was the only independent factor significantly related to survival after initiation and tolerance of NIPPV. We also evaluated the independent prognostic power of BMI in our cohort using different thresholds and found that values Ͻ21 were associated with an increased risk of death. However, in the absence of an independent sample to validate the cut point, this result should be interpreted with caution and other studies are needed to confirm BMI predictive power. BMI is a surrogate of nutritional status and malnutrition has been recently proposed as a negative prognostic factor for survival in ALS patients 15 and in other neurologic 16 and non-neurologic disorders. 17 Our study, then, strengthens the role of nutritional assessment in ALS management and emphasizes the importance of nutritional surveillance of ALS patients at the time of NIPPV introduction. Moreover, BMI is simple to calculate and requires no special equipment. This makes it a practical tool of potentially widespread applicability. A possible limitation of the study is that we have not implemented the revised version of the ALS-FRS, which gives greater attention to pulmonary function than the original version, 18 and future studies should assess its prognostic value in patients undergoing NIPPV.
Furthermore, the relatively small sample size of our exploratory study might limit the power to rule out negative regressors as truly negative and only allows the detection of factors associated with large adjusted odds ratios to test in larger confirmatory studies.
Another limitation is the lack of a randomized or blinded design, and the prospective nature of the study could be exposed to some biases. However, because there is substantial evidence that NIPPV can improve quality of life and prolong survival in ALS patients, this type of study is difficult to carry out for ethical reasons, and at present, only one randomized, controlled trial has been conducted. 10 Moreover, our ALS population, consisting of a group of ambulatory patients referred for the first time to an ALS clinic, could closely reflect patients encountered in the clinical practice.
